-
Mashup Score: 4Development of Patient-Derived Lymphoma Tumoroids for Studying Follicular Lymphoma | Blood Cancers Today - 1 day(s) ago
Follicular lymphoma demonstrates a strong interplay with its tumor microenvironment, influencing disease progression and therapy resistance.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3
Researchers say barriers such as time constraints and financial limitations complicate fertility counseling and preservation for patients with lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
Adolescents and young adults with non-Hodgkin #lymphoma face potential fertility challenges due to treatment. A study presented at #ASH24 by @NadiaToumeh, of @MayoMN_IMRES, evaluated fertility preservation among patients aged 18-50. 💡 Learn more: https://t.co/naxukAJ4G9 https://t.co/glWhFxBOOf
-
-
Mashup Score: 0
Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with relapsed or refractory follicular #lymphoma, Monjuvi in addition to Revlimid and Rituxan led to a 57% reduction in the risk of disease progression or death versus the placebo plus Revlimid and Rituxan, as presented at #ASH24. https://t.co/ObZ7t4jHTH
-
-
Mashup Score: 0
The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
The real-world effectiveness of Monjuvi in U.S. patients with relapsed or refractory diffuse large B-cell #lymphoma was confirmed, along with factors associated with survival, as presented at #ASH24. https://t.co/S3m8hoay4X
-
-
Mashup Score: 1Impact of Histologic Transformation on Prognosis in Early Relapsing Follicular Lymphoma | Blood Cancers Today - 4 day(s) ago
Patients with follicular lymphoma experiencing early progression or death within twenty four months after immunochemotherapy face poor outcomes.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
❓ What is the impact of histologic transformation on prognosis in early relapsing follicular #lymphoma? 💡 A study presented at #ASH24 by @DrCarlaCasulo, of @WilmotCancer, lends insight. 📰 https://t.co/TZRRihtz8G https://t.co/R1piTBCoWe
-
-
Mashup Score: 4OLYMPIA-1 Trial: Odronextamab Demonstrates 100% ORR, CR Rate in High-Risk Follicular Lymphoma | Blood Cancers Today - 20 day(s) ago
Odronextamab monotherapy showed promising efficacy in patients with high-risk, grade 1-3a follicular lymphoma in the phase III Olympia-1 trial.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
💯 In the OLYMPIA-1 trial, odronextamab demonstrated a 100% ORR and CR rate in patients with high-risk follicular #lymphoma. Read more from the study presented at #ASH24 by Elizabeth Brem, MD, of @UCIrvineHealth. ➡️ https://t.co/kNGlkTetZO https://t.co/ssBkoLokei
-
-
Mashup Score: 2Epcoritamab Triplet Shows ‘Deep, Durable Responses’ in Follicular Lymphoma in Two-Year Follow-Up | Blood Cancers Today - 24 day(s) ago
Fixed-duration epcoritamab with rituximab plus lenalidomide drives deep and durable responses in patients with relapsed or refractory follicular lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
⭐ EPCORE NHL-2 trial ⭐ Fixed-duration epcoritamab with rituximab plus lenalidomide drives deep and durable responses in patients with R/R follicular #lymphoma. The study was presented at #ASH24 by Lorenzo Falchi, MD, of @MSKCancerCenter. ➡️ https://t.co/xd1xRvhurz https://t.co/FpU98oiHkF
-
-
Mashup Score: 1Tisagenlecleucel Elicits Robust Responses in Relapsed or Refractory FL | Blood Cancers Today - 25 day(s) ago
Catherine Thieblemeont, MD presented phase II data showing the clinical activity of tisagenlecleucel in patients with relapsed or refractory follicular lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Tisa-cel yielded robust responses with favorable safety for more than four years post-CAR T-cell infusion in patients with R/R follicular #lymphoma. Read more about the ELARA trial presented at #ASH24 by Catherine Thieblemeont, MD (@HopSaintLouis). ➡️ https://t.co/LgXYFwIhuv https://t.co/IAczbwfLj8
-
-
Mashup Score: 2Treatment Discontinuations Reduced With Jaypirca in CLL, SLL - 26 day(s) ago
Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients with previously treated CLL or SLL.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
For patients with previously treated chronic lymphocytic leukemia or small lymphocytic #lymphoma, Jaypirca improved progression-free survival with low rates of treatment discontinuation versus the investigator’s choice of treatment, as presented at #ASH24. https://t.co/mwGxY0A4to
-
-
Mashup Score: 0
Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Patients with mantle cell #lymphoma did not show improved survival after receiving consolidative autologous hematopoietic cell transplant with Rituxan in their first complete remission with undetectable minimal residual disease, as presented at #ASH24. https://t.co/PCirE01wIe
-
🔬 Researchers have developed patient-derived lymphoma tumoroids for studying follicular #lymphoma. 📝 Data were presented at #ASH24 by Ruben Gimenez, MSc, of @idibaps. 💡 Learn more: https://t.co/O0vAobt2RC https://t.co/TkbTMeyVpn